COPD diagnosis
AssigneeAposcience AG
InventorJan Hendrik Ankersmit
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for diagnosing chronic obstructive pulmonary disease (COPD) in a human subject or the risk of a human subject to develop COPD comprising the steps of: —providing a sample from a human subject, —determining the amount of caspase-cleaved cytokeratin-18 (ccCK-18), histones, heat shock protein 27 (HSP27), heat shock protein 70 (HSP70) and/or heat shock protein 90 alpha (HSP90 alpha) in said sample, —diagnosing COPD when the amount of ccCK-18, histones, HSP27, HSP70 and/or HSP90 alpha is increased compared to the amount of ccCK-18, histones, HSP27, HSP70 and/or HSP90 alpha in healthy human subjects, or—diagnosing the risk to develop COPD when the amount of ccCK-18, histones and/or HSP70 is reduced compared to the amount of ccCK-18, histones and/or HSP70 in healthy human subjects.
Claims15
A method for diagnosing chronic obstructive pulmonary disease (COPD) in a human subject or the risk of a human subject to develop COPD comprising the steps of:
- providing a sample from a human subject,
- determining the amount of caspase-cleaved cytokeratin-18 (ccCK-18), histones, heat shock protein 27 (HSP27), heat shock protein 70 (HSP70) and/or heat shock protein 90 alpha (HSP90 alpha) in said sample,
- diagnosing COPD when the amount of ccCK-18, histones, HSP27, HSP70 and/or HSP90 alpha is increased compared to the amount of ccCK-18, histones, HSP27, HSP70 and/or HSP90 alpha in healthy human subjects, or
- diagnosing the risk to develop COPD when the amount of ccCK-18, histones and/or HSP70 is reduced compared to the amount of ccCK-18, histones and/or HSP70 in healthy human subjects.
A method for discriminating between COPD stage I/II and COPD stage III/IV in a human subject comprising the steps of:
- providing a sample from a human subject suffering from COPD,
- determining the amount of caspase-cleaved cytokeratin-18 (ccCK-18), histones, heat shock protein 27 (HSP27) and/or heat shock protein 70 (HSP70) in said sample,
- diagnosing COPD stage I/II when the amount of ccCK-18, histones, and/or HSP27 is reduced compared to the amount of ccCK-18, histones and/or HSP27 determined in a sample from a human subject suffering from COPD stage III/IV and/or when the amount of HSP70 is increased compared to the amount of HSP70 determined in a sample from a human subject suffering from COPD stage III/IV, or
- diagnosing COPD stage III/IV when the amount of ccCK-18, histones and/or HSP27 is increased compared to the amount of ccCK-18, histones and/or HSP27 determined in a sample from a human subject suffering from COPD stage I/II and/or when the amount of HSP70 is reduced compared to the amount of HSP70 determined in a sample from a human subject suffering from COPD stage I/II.
A method for monitoring the progress of chronic obstructive pulmonary disease (COPD) in a human subject comprising the steps of:
- providing a sample from a human subject,
- determining the amount of caspase-cleaved cytokeratin-18 (ccCK-18), histones, heat shock protein 27 (HSP27) and/or heat shock protein 70 (HSP70) in said sample,
- comparing the amount of ccCK-18, histones, HSP27 and/or HSP70 in the sample of said human subject with the amount of ccCK-18, histones, HSP27 and/or HSP70 in a sample from said human subject determined in an earlier sample of said human subject.
Dependencies are inferred from the claim text.